Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for the pertussis-free environment.

The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-dtap-tdap-vaccines-2019-713

Factors such as high birth rate, increase in a number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of the diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quarrel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine.

The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas the whole-cell vaccine, is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market.

In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.

The global DTaP and Tdap Vaccines market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019–2025.This report focuses on DTaP and Tdap Vaccines volume and value at global level, regional level and company level. From a global perspective, this report represents overall DTaP and Tdap Vaccines market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

• Sanofi Pasteur
• GlaxoSmithKline
• Protein Sciences Corporation
• Novartis AG
• Seqirus
• Merck Sharp & Dohme Corp
• Astellas Pharma US, Inc
• Pfizer Inc
• Johnson & Johnson
• Lanzhou Institute of Biological Products Co., Ltd
• AstraZeneca
• Emergent BioSolutions Inc

Segment by Regions

• North America
• Europe
• China
• Japan

Segment by Type

• DTaP
• Td
• Tdap

Segment by Application

• Adult
• Pediatric

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-dtap-tdap-vaccines-2019-713

Table of content

Executive Summary
1 DTaP and Tdap Vaccines Market Overview
1.1 Product Overview and Scope of DTaP and Tdap Vaccines
1.2 DTaP and Tdap Vaccines Segment by Type
1.2.1 Global DTaP and Tdap Vaccines Production Growth Rate Comparison by Type (2014–2025)

2 Global DTaP and Tdap Vaccines Market Competition by Manufacturers
2.1 Global DTaP and Tdap Vaccines Production Market Share by Manufacturers (2014–2019)
2.2 Global DTaP and Tdap Vaccines Revenue Share by Manufacturers (2014–2019)
2.3 Global DTaP and Tdap Vaccines Average Price by Manufacturers (2014–2019)

3 Global DTaP and Tdap Vaccines Production Market Share by Regions
3.1 Global DTaP and Tdap Vaccines Production Market Share by Regions
3.2 Global DTaP and Tdap Vaccines Revenue Market Share by Regions (2014–2019)
3.3 Global DTaP and Tdap Vaccines Production, Revenue, Price and Gross Margin (2014–2019)

Key Que Answered in this report:

1. What will the DTaP and Tdap Vaccines Market?
2. What are the key factors driving the Global DTaP and Tdap Vaccines Market?
3. What are the key market trends in the DTaP and Tdap Vaccines Market?
4. improve pasting the growth of this DTaP and Tdap Vaccines Market?
5. What are the challenges to the DTaP and Tdap Vaccines Market?
6. What are the market opportunities and threats faced by the vendors in the Global DTaP and Tdap Vaccines Market?
7. What are the key outcomes of the five forces analysis of the DTaP and Tdap Vaccines Market?

What is our report offers:

Strategic suggestions and proposals for the beginners to understand
Assessments of the market share from different countries and regions were conducted
Top key market players, market share analysis included.
The market observations such as constraints, drivers, threats, opportunities, investment opportunities, challenges, and recommendations are added.
The competitive landscaping mappings of the ongoing trends are discussed.
Based on the market estimations, the strategic recommendations are made in the business segments

CONTACT US:
276 5th Avenue, New York, NY 10001, United States
International: (+1) 646 781 7170 / +91 8087042414
Email: help@grandresearchstore.com

Follow Us On LinkedIn:- https://www.linkedin.com/company/grand-research-store/